Short answer
Taysha Gene Therapies, Inc. (TSHA) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$47M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$47M
- −73.5% YoY · −10.0% QoQ
- EPS (diluted)
- −$0.12
- −33.3% YoY · +0.0% QoQ
Source: XBRL data from the Taysha Gene Therapies, Inc. (TSHA) Q2 2026 10-Q on SEC EDGAR. USD.
Taysha Gene Therapies, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $0; no approved products or product-sale revenue
- Net loss $89.0M for six months ended June 30, 2026; accumulated deficit $800.3M
- REVEAL pivotal trial: 17 patients dosed; topline interim data expected first half 2027
- Cash deployment: $3.0M investing outflow for Abeona milestone payment
- Ongoing headwinds: significant expenses and operating losses expected as clinical and manufacturing activities expand
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added risk trigger identifiable from the submitted text
- No regulatory, legal, compliance, operational, competitive, market, or financial risks disclosed in the submitted text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Taysha Gene Therapies, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.